...in October with $108 million. Also participating in the series B were Surveyor Capital, Invus, Wellington Management...
...– Epidermal growth factor receptor 2 BC Staff CVnCoV CT-0508 (CARMA-0508) ARGX-113 (efgartigimod) Bayer AG CureVac N.V. Boxer Capital EcoR1 Capital Omega Funds Vida Ventures Surveyor Capital Invus Wellington Management OrbiMed Casdin...

...mature pipeline.”Beyond the two lead investors, Affinivax’s latest round included new investors T. Rowe Price, Wellington Management...

...already begun to pursue biotech investments. Last year, Wellington Management...

...Janus Henderson Investors, Logos Capital, OrbiMed Advisors, T. Rowe Price, Venrock, Viking Global Investors and Wellington Management...

...$91 million into the union; leader Fairmount Funds Management joins Venrock, BVF Partners, Cormorant, Perceptive Advisors, Wellington Management...

...Management, Vida Ventures, Viking Global Investors and Wellington Management.TARGETSSHP-2...

...$100MShanghai and Suzhou-based Gracell Biotechnologies Inc. raised a $100 million series C round led by Wellington Management...

...Capital, Ally Bridge, Avidity Partners, Deerfield Management, Irving Investors, Monashee Investment Management, OrbiMed Advisors and Wellington Management...

...round. Its existing investors include BVF Partners, Logos Capital, Janus Henderson Investors, Cormorant Asset Management, Wellington Management...

...roundNeurodegenerative disease company Escape Bio Inc. raised $73 million in a crossover round led by Wellington Management...